Your Health. Your Family. Your Choice.
Administered by: Other Purchased by: ?
Life Threatening? No
Write-up: Unknown cause of death; Mobility decreased; Sleep restless; Nausea; Dizziness; General physical health deterioration; This is a spontaneous report from a contactable consumer downloaded from a regulatory authority-WEB, regulatory authority number FI-FIMEA-20211659. An 88-year-old male patient received BNT162B2 (COMIRNATY), via an unspecified route of administration on 22Feb2021 (Batch/Lot Number: EJ6790) as single dose for COVID-19 immunisation. Medical history included VV1 pacemaker (cardiac pacemaker insertion) on 31Jan2020: insertion of a permanent VV1 pacemaker, gallstone removal from the beginning of 2020: "monitored from 2002 onwards", hypertension and anticoagulant therapy. Concomitant medications included enalapril maleate (LINATIL) taken for hypertension, start and stop date were not reported; apixaban (ELIQUIS) taken for anticoagulant therapy, start and stop date were not reported; calcium chloride dihydrate, potassium chloride, sodium chloride (HUMIDOSE) taken for an unspecified indication, start and stop date were not reported. On 23Feb2021, the patient experienced mobility decreased, sleep restless, nausea, dizziness and general physical health deterioration. The day after the vaccination there was difficulty moving due to dizziness, he had to take support from the walls while walking and had nausea and restless sleep. On 09Mar2021, he had difficulty getting out of bed. His overall condition deteriorated after vaccination. The patient died (unknown cause of death) on 09Mar2021. The results of the forensic autopsy research were not yet available. No follow-up attempts are needed. No further information is expected.; Reported Cause(s) of Death: Unknown cause of death
Copyright © 2021 National Vaccine Information Center. All rights reserved.
21525 Ridgetop Circle, Suite 100, Sterling, VA 20166